Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11213625 | 0.85 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2PKMHPGDRAB9A | |
| SCHEMBL27905947 | 0.85 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2PKMHPGDRAB9A | |
| SCHEMBL16364100 | 0.82 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2PKMHPGDRAB9A | |
| SCHEMBL11683297 | 0.82 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2PKMHPGDRAB9A | |
| SCHEMBL16266236 | 0.81 | SMN1; SMN2 (1.00) | ALDH1A1SMN1; SMN2PKMHPGDRAB9A | |
| SCHEMBL18906003 | 0.81 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2PKMHPGDRAB9A | |
| SCHEMBL16272275 | 0.81 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2PKMHPGDRAB9A | |
| SCHEMBL5123738 | 0.81 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2PKMHPGDRAB9A | |
| SCHEMBL237337 | 0.81 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2PKMHPGDRAB9A | |
| SCHEMBL2969896 | 0.79 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2PKMHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004765-A1 | New compounds | BIOVITRUM AB (SE) | 2007-01-04 | — | — | US | claimed |
| WO-2006122931-A1 | BETA-CARBOLINE DERIVATIVES AND THERI USE AS GHSR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2006-11-23 | — | — | WO | claimed |
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | BIOVITRUM AB (SE) | 2005-12-29 | — | — | US | claimed |
| WO-2005048916-A2 | TETRAHYDROSPIRO-BETA-CARBOLINE-1,3 '-PYRROLIDINE DERIVATIVES AND THEIR USE IN GHSR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2005-06-02 | — | — | WO | claimed |
| EP-0131374-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PENEM DERIVATIVES | PFIZER INC. (US) | 1988-11-23 | — | — | EP | claimed |
| US-4725678-A | ANTIBIOTICS | PFIZER INC. (US) | 1988-02-16 | — | — | US | claimed |
| US-4619783-A | BACTERICIDES | PFIZER INC. (US) | 1986-10-28 | — | — | US | claimed |
| US-4595539-A | Containing acid or ester groups and sulfur | PFIZER INC. (US) | 1986-06-17 | — | — | US | claimed |
| EP-0131374-A1 | Process and intermediates for the preparation of penem derivatives | PFIZER INC. (US) | 1985-01-16 | — | — | EP | claimed |
| EP-0128725-A1 | Preparation of penem derivatives | PFIZER INC. (US) | 1984-12-19 | — | — | EP | claimed |
| EP-0092830-A2 | Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and their application | CIBA-GEIGY AG (CH) | 1983-11-02 | — | — | EP | claimed |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | disclosed |
| US-20070004765-A1 | New compounds | BIOVITRUM AB (SE) | 2007-01-04 | — | — | US | disclosed |
| US-4619783-A | BACTERICIDES | PFIZER INC. (US) | 1986-10-28 | — | — | US | disclosed |
| US-4595539-A | Containing acid or ester groups and sulfur | PFIZER INC. (US) | 1986-06-17 | — | — | US | disclosed |
| EP-0131374-A1 | Process and intermediates for the preparation of penem derivatives | PFIZER INC. (US) | 1985-01-16 | — | — | EP | disclosed |
| EP-0128725-A1 | Preparation of penem derivatives | PFIZER INC. (US) | 1984-12-19 | — | — | EP | disclosed |
| EP-0092830-A2 | Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and their application | CIBA-GEIGY AG (CH) | 1983-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | GHSR, GHRHR, PRLHR | ALDH1A1 1919/4885SMN1; SMN2 2065/4885PKM 2997/4885 |
| US-20070004765-A1 | New compounds | GHSR, GIPR, PRLHR | ALDH1A1 763/4885SMN1; SMN2 2365/4885PKM 2650/4885 |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | CCL2, CCR2, CXCL10 | ALDH1A1 1361/4885SMN1; SMN2 4250/4885PKM 1536/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | ALDH1A1 306/4885SMN1; SMN2 4648/4885PKM 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.